Microplastics detected in human organs, raising EU regulatory pressure
A new report showing microplastics in human organs and cancer tissues is pressuring the EU to accelerate regulation, with significant implications for European industry in the 2024-2029 legislative cycle.
A report published on Wednesday by the Plastic Soup Foundation and Green Impact warns that current EU legislation is failing to prevent microplastics from infiltrating human blood, breast milk, lungs, brain tissue, placentas and children's urine. The findings challenge the adequacy of the bloc's existing chemical and product regulations as it enters a new legislative term.
Drawing on peer-reviewed science, the report links micro- and nanoplastics to intestinal disturbance, cardiovascular and reproductive toxicity, neurotoxicity and metabolic disruption in mammals. The underlying mechanisms involve oxidative stress, inflammation and physical damage. Furthermore, the particles have been found in higher concentrations in human lung, colorectal and prostate cancer tissues compared to healthy tissue. While direct evidence in humans remains limited and it is unclear if the plastics cause cancer or simply accumulate in tumours, the preclinical data presents a significant liability for regulators.
The implications for Europe's vast plastics sector are substantial. The report specifically flags polyamide, polypropylene and polyvinyl chloride (PVC) as categories of concern. These materials are foundational to European manufacturing, widely used in automotive parts, construction, textiles and food packaging. Should the EU decide to act on these findings, companies across these supply chains could face stringent new material restrictions, compliance costs and urgent demands to find substitutes.
The pressure to intervene is amplified by the data on children. A highlighted study of 1,000 children aged six to nine (Dong et al., 2025) found a significant association between the presence of these specific microplastics in urine and behavioural problems. As public scrutiny over product safety grows, investors in consumer-facing brands may begin to price in the risk of regulatory crackdowns.
Advocates argue the political window for action is open. "Europe has the scientific evidence and holds the political mandate to protect public health. What is missing is the ambition to legislate at the pace the science demands," said Gaia Angelini, president of Green Impact. Maria Westerbos, founder of the Plastic Soup Foundation, framed the urgency around the coming political term. "It is a public health emergency that the EU’s 2024–2029 legislative cycle has a unique opportunity to address," she said.
